These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 7725368)

  • 1. Aminopyrine metabolism in man: the acetylation of aminoantipyrine cosegregates with acetylation of caffeine.
    Agúndez JA; Carrillo JA; Martínez C; Benítez J
    Ther Drug Monit; 1995 Feb; 17(1):1-5. PubMed ID: 7725368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validity of saliva samples for the estimation of dipyrone metabolites pharmacokinetics.
    Caraco Y; Zylber-Katz E; Granit L; Levy M
    Arzneimittelforschung; 1993 Nov; 43(11):1204-8. PubMed ID: 8292065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolism of aminopyrine and derivatives in man: in vivo study of monomorphic and polymorphic metabolic pathways.
    Agúndez JA; Martínez C; Benítez J
    Xenobiotica; 1995 Apr; 25(4):417-27. PubMed ID: 7645307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dipyrone metabolism in liver disease.
    Zylber-Katz E; Caraco Y; Granit L; Levy M
    Clin Pharmacol Ther; 1995 Aug; 58(2):198-209. PubMed ID: 7648770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acetylator phenotyping in patients with malignant lymphomas, using caffeine as the metabolic probe.
    William BM; Abdel-tawab AM; Hassan EA; Mohamed OF
    Pol J Pharmacol; 2004; 56(4):445-9. PubMed ID: 15520499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Caffeine as a potential indicator for acetylator status.
    Rankin RB; Hudson SA; Fell AF
    J Clin Pharm Ther; 1987 Feb; 12(1):47-51. PubMed ID: 3449563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impairment of the metabolism of dipyrone in asymptomatic carriers of the hepatitis-B virus does not occur in rapid acetylators.
    Levy M; Safadi R; Zylber-Katz E; Granit L; Caraco Y
    Eur J Clin Pharmacol; 2001 Sep; 57(6-7):461-5. PubMed ID: 11699610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma kinetics of dipyrone metabolites in rapid and slow acetylators.
    Levy M; Flusser D; Zylber-Katz E; Granit L
    Eur J Clin Pharmacol; 1984; 27(4):453-8. PubMed ID: 6519153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Segregation analyses of four urinary caffeine metabolite ratios implicated in the determination of human acetylation phenotypes.
    Vincent-Viry M; Pontes ZB; Gueguen R; Galteau MM; Siest G
    Genet Epidemiol; 1994; 11(2):115-29. PubMed ID: 8013893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Caffeine acetylator phenotyping during maturation in infants.
    Pariente-Khayat A; Pons G; Rey E; Richard MO; D'Athis P; Moran C; Badoual J; Olive G
    Pediatr Res; 1991 May; 29(5):492-5. PubMed ID: 1896253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Variability of caffeine metabolism in humans.
    Kalow W
    Arzneimittelforschung; 1985; 35(1A):319-24. PubMed ID: 3838675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of liver disease on urine caffeine metabolite ratios.
    Denaro CP; Wilson M; Jacob P; Benowitz NL
    Clin Pharmacol Ther; 1996 Jun; 59(6):624-35. PubMed ID: 8681487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Formation and excretion of dipyrone metabolites in man.
    Zylber-Katz E; Granit L; Levy M
    Eur J Clin Pharmacol; 1992; 42(2):187-91. PubMed ID: 1618251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between metabolic phenotype of N-acetylation and bladder cancer.
    Cui X; Guo R; Xu Z; Wang B; Li C
    Chin Med J (Engl); 2000 Apr; 113(4):303-5. PubMed ID: 11775223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between in vivo acetylator phenotypes and cytosolic N-acetyltransferase and O-acetyltransferase activities in human uroepithelial cells.
    Frederickson SM; Messing EM; Reznikoff CA; Swaminathan S
    Cancer Epidemiol Biomarkers Prev; 1994; 3(1):25-32. PubMed ID: 8118381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acetylation polymorphism of caffeine in a Japanese population.
    Hashiguchi M; Ebihara A
    Clin Pharmacol Ther; 1992 Sep; 52(3):274-6. PubMed ID: 1526084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of N-acetyltransferase activity: should caffeine phenotyping and NAT2 genotyping be used interchangeably in epidemiological studies?
    Le Marchand L; Sivaraman L; Franke AA; Custer LJ; Wilkens LR; Lau AF; Cooney RV
    Cancer Epidemiol Biomarkers Prev; 1996 Jun; 5(6):449-55. PubMed ID: 8781741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative bioavailability of two oral metamizole formulations. Influence of the acetylation phenotype.
    Bacracheva N; Drenska A; Gorantcheva J; Tyutyulkova N; Vlahov V
    Arzneimittelforschung; 1995 Mar; 45(3):282-5. PubMed ID: 7741785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between high incidence of adverse dapsone reactions and slow acetylate phenotype or low plasma/lymphocyte glutathione level.
    Guo R; Thormann W; Lauterberg B
    Chin Med J (Engl); 1996 Dec; 109(12):933-6. PubMed ID: 9275325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N-acetylator variability in Down's syndrome: characterization with caffeine.
    Morris ME; Griener JC; Msall ME
    Clin Pharmacol Ther; 1989 Sep; 46(3):359-66. PubMed ID: 2528436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.